Glactone Pharma has developed a pipeline of novel STAT3 (signal transducer and activator of transcription 3) inhibitors for the use in immuno-oncology and for the treatment of drug resistant cancers (including castration resistant prostate cancer). STAT3 is directly involved in tumor mediated immune suppression and in mechanisms leading to resistance to targeted therapies, making it an ideal target in combination treatments.
Our objective is to take a candidate drug into clinical trials. Thereafter the intention is to divest the company to a larger company that can secure the further development, registration and commercialization of this novel treatment, making it available to patients, and to address large unmet medical needs.
Glactone Pharma AB is a privately held Swedish biotech company founded in 2012 by the innovator group and the Swedish company PULS (Partners for Development Investments in Life Sciences P.U.L.S. AB.).
PULS is a life science company with a unique combination of scientists and industrialists who together with innovators are commercializing ideas by providing capital, know-how and committed partnership. PULS’s involvement in the project development of Glactone Pharma is based on a proven business model securing return on investment. Read more about www.pulsinvest.se. For investors www.pulsinvest.se/investors/.
Glactone Pharma is founded on research that has demonstrated that the natural product galiellalactone can inhibit the growth of prostate cancer cells. With these results as the starting point the company has focused on discovering and developing novel drug-like compounds that display efficacious and selective STAT3 inhibition in vitro and in specific immune-oncology and prostate cancer models.
The company is based on the application of long-standing research from Lund University and Skåne University Hospital in Sweden, and Cordoba University in Spain. To read more about our research, see Publications.
To initiate a project and take it all the way to a successful exit requires an organization with the right people in the right positions at the right time.
Glactone Pharma is organized to represent all the necessary skills and competences of an innovative and successful biotech company.
The company is run as a virtual organization with project management, financing, accounting and administrative support being provided by PULS, www.pulsinvest.se.
Glactone Pharma has a highly dedicated and experienced management team and board which are key to the project development. Furthermore, Glactone Pharma has active collaborations with the innovators and the scientific advisory board, providing the company with world class scientific input.
The innovators behind Glactone Pharma are Olov Sterner, Professor of Organic Chemistry at Lund University Hospital, Rebecka Hellsten and Martin Johansson from Lund University Hospital, Anders Bjartell, Professor of Urology at Skåne University Hospital in Malmö, Lund University, Lund (all in Sweden); and Eduardo Muñoz at the University of Cordoba and IMIBIC, in Spain.
In addition, Glactone Pharma makes efficient use of an established international network of CROs and consultants and has access to PULS’s extensive partner network.